BHC - Bausch Health Companies Inc.

NYSE - NYSE Prix différé. Devise en USD
27,38
+0,37 (+1,37 %)
À la clôture : 4:00PM EST
Le graphique des titres n’est pas pris en charge par votre navigateur actuel
Clôture précédente27,01
Ouverture26,98
Offre25,70 x 1400
Vente0,00 x 1800
Var. jour26,74 - 27,44
Sur 52 semaines17,20 - 27,44
Volume2 738 264
Volume moyen3 604 620
Cap. boursière9,656B
Bêta (mensuel sur 3 exercices)0,87
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-1,75
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividende2010-11-10
Objectif sur 1 an30,75
  • Globe Newswire

    Nicox: Second Quarter 2019 Business Update and Financial Highlights

    Press Release Nicox: Second Quarter 2019 Business Update and Financial Highlights * Enrollment completed in the NCX 470 Phase 2 clinical trial in patients with glaucoma and ocular hypertension with results expected in early Q4 of this year   * Q2 2019 net revenue, including licensing payments, of €5.2 million July 17, 2019– release at 7:30 am CET Sophia Antipolis, France   Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q2 2019 operational highlights, revenue and cash position for Nicox and its subsidiaries (the “Nicox Group”), as well as key upcoming milestones. Michele Garufi, Chairman and Chief Executive Officer of Nicox, said, “Completion of enrollment in the NCX 470 glaucoma trial was a major step in delivering on the strategy for Nicox and keeps us on track for reporting the results of this study in early Q4, along with those of the NCX 4251 blepharitis trial later in the quarter.  In preparation for the next steps with these two programs, we are strengthening the development function and have hired Dr. José Boyer into the new position of Vice President of Clinical Development.  Our strategic business development activities continue to be fruitful with the recent NCX 4251 licensing deal in China consolidating our partnership there with Ocumension and we are expanding our global licensing efforts outside the US and Europe in order to optimize the value of our portfolio.” Key Upcoming Milestones * NCX 470 Phase 2 results: Following completion of enrollment, top-line data from the first efficacy Phase 2 clinical trial for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension expected in early Q4 of this year. * NCX 4251 Phase 2 results: Trial in patients with acute exacerbations of blepharitis continuing on track for top-line data expected in Q4 of this year. * ZERVIATE partnering outside of the U.S.: Multiple discussions ongoing for potential new licensing agreements in significant markets. * ZERVIATE U.S. launch: Commercial launch of ZERVIATE (cetirizine ophthalmic solution), 0.24% in the U.S. is expected by our partner Eyevance Pharmaceuticals in H1 2020 Second Quarter 2019 and Recent Operational Highlights * The total number of prescriptions for VYZULTA in the U.S. in the second quarter of 2019 increased by 17% compared to Q1 20191 and by 161% compared to the second quarter 20181. * Earlier this week we announced that we had completed enrollment of patients in our multicenter, United States (U.S.) Phase 2 clinical study evaluating NCX 470, a novel second generation NO-donating bimatoprost analog, being tested in patients with glaucoma or ocular hypertension for its ability to lower IOP.  This study is a head-to-head comparison of once-daily administration of three different doses of NCX 470 versus latanoprost, which is the most widely prescribed first-line therapy for glaucoma and ocular hypertension.  Top-line data of the study is expected early in Q4 of this year. * In July 2019 we received a $3 million milestone payment from partner Eyevance Pharmaceuticals, triggered by the completion of the regulatory and manufacturing activities under Nicox’s responsibility necessary for the final manufacturing milestone payment in preparation for the launch of ZERVIATE in the U.S.  From now on all manufacturing and regulatory responsibilities, together with decisions on launch timing, lie with Eyevance.  Eyevance has informed Nicox that the launch of ZERVIATE in the U.S. is currently projected in H1 2020. * In July 2019 we entered into an exclusive license agreement with Ocumension Therapeutics for the development and commercialization of our product candidate, NCX 4251, currently in a Phase 2 trial in the U.S. in patients with acute exacerbations of blepharitis, for a territory comprising mainland China, Hong Kong, Macau and Taiwan.  Under the terms of the agreement, Nicox received an upfront payment of €2 million and may potentially receive development and sales milestones of up €10 million together with tiered royalties of between 5% and 10% on sales of NCX 4251. * VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has now been made available in Canada by our partner Bausch + Lomb, following approval there in December 2018. * We have amended our bond financing agreement with Kreos Capital signed in January 2019.  We have already drawn down €8 million under the agreement.  The original agreement allowed for Nicox to draw down a second tranche of €7 million on August 1st, 2019, and a third tranche of €5 million on November 1st, 2019.  Under the amendment, Nicox may draw down either €7 million or €12 million on November 1st, 2019, subject to notice to Kreos by October 10th, 2019. Full details of the bond financing agreement can be found in the Press Release of January 25, 2019 - http://www.nicox.com/assets/files/EN-_Kreos-PR_201901.pdfStrengthening Management in Clinical Development We appointed José L. Boyer, Ph.D., to the newly-created position of Vice President of Clinical Development, effective June 10, 2019.  In this position, Dr. Boyer will be responsible for leading our clinical development activities, and will report to Tomas Navratil, Ph.D., Executive Vice President, Head of Development of Nicox.  Dr. Boyer has more than 30 years of experience in academic research and drug development in the pharmaceutical industry including senior leadership roles in ophthalmology development at Parion Biosciences and Inspire Pharmaceuticals. Second Quarter 2019 Financial Highlights As of June 30, 2019, the Nicox Group had cash and cash equivalents of €17.3 million as compared with €23.5 million at March 31, 2019 and €22.1 million at end December 31, 2018.  These cash and cash equivalents do not include the €2 million upfront payment from Ocumension nor the $3 million milestone payment from Eyevance received in July.  Net revenue2 for the second quarter of 2019 was €5.2 million versus €0.2 million in the second quarter of 2018. Only figures at 31 December 2018 are audited.  All figures of this press release are non-audited.  Notes   1. Bloomberg data, comparing the period of the weeks ending 5 April 2019 to 28 June 2019 with the periods of the weeks ending 4 January 2019 to 29 March 2019 and 6 April 2018 to 29 June 2018 2. Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss  About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma.  Our portfolio has three programs in development including NCX 470, a novel, second-generation NO-donating bimatoprost analog, for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis.  Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Cyclerion).  In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE™ (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyevance Pharmaceuticals, LLC.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage Bryan, Garnier & Co    Hugo Solvet   Paris, France H.C. Wainwright & Co   Yi Chen  New York, U.S.    The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development   T +33 (0)4 97 24 53 00 communications@nicox.com Investors & Media United States & Europe LifeSci Advisors, LLC Hans Herklots T +41 79 598 71 49   hherklots@lifesciadvisors.comMedia France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 sophie@lifesciadvisors.com Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 4th chapter of the ‘Document de référence, rapport financier annuel et rapport de gestion 2018’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2019 which are available on Nicox’s website (www.nicox.com). Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99  Attachment * EN_Q2_2019_Results_PR_Final_1a_clean_July17.2019

  • Globe Newswire

    Nicox First Quarter 2019 Business Update and Financial Highlights

    Press ReleaseNicox First Quarter 2019 Business Update and Financial Highlights ………………………………………………………………………………………………………………………….. * Total VYZULTA® prescriptions for the first quarter 2019 increased by 18% compared to the fourth quarter 2018 and by 360% compared to the first quarter 2018   * NCX 470 Phase 2 clinical trial in glaucoma over 85% enrolled * NCX 4251 Phase 2 clinical trial initiated in blepharitis * ZERVIATE multiple licensing discussions ongoing ex-U.S. ………………………………………………………………………………………………………………………….. April 18, 2019 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q1 2019 operational highlights, revenue and cash position for Nicox and its subsidiaries (the “Nicox Group”), as well as key upcoming milestones.Michele Garufi, Chairman and Chief Executive Officer of Nicox, said, “With two exciting programs in advanced clinical development and two products approved in the U.S. we are continuing apace to fully leverage our scientific, clinical, and commercial assets.  Enrollment has now reached over 85% in the NCX 470 glaucoma clinical trial, and both this and the NCX 4251 blepharitis trial should generate topline results in Q4 of this year.  We expect our recurrent revenues to ramp up as Bausch + Lomb progresses the international rollout of VYZULTA, and with the launch by Eyevance of ZERVIATE in the U.S.  In addition, our ongoing discussions for ZERVIATE outside of the U.S. could result in agreements in the near future with further upfront, milestone and royalty payments.”Key Upcoming Milestones * NCX 470 Phase 2 results: Top-line data from the NCX 470 Phase 2 clinical trial for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension expected in Q4 of this year. * NCX 4251 Phase 2 results: Phase 2 clinical trial in patients with acute exacerbations of blepharitis ongoing with top-line data expected in Q4 of this year. * ZERVIATE U.S. launch: Commercial launch of ZERVIATE (cetirizine ophthalmic solution), 0.24% in the U.S. planned by our partner Eyevance Pharmaceuticals for summer of this year.  Nicox eligible for up to $3 million of a potential future milestone payment from Eyevance related to certain regulatory and near-term manufacturing objectives, which are expected to be received prior to the U.S. launch. * ZERVIATE ex-US partnering: Multiple discussions ongoing for potential new licensing agreements in significant markets. * Nicox’s ophthalmology programs to be presented at key scientific conferences including the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. First Quarter 2019 and Recent Operational Highlights * The total number of prescriptions for VYZULTA in the U.S. in the first quarter of 2019 increased by 18% compared to Q4 20181 and by 360% compared to the first quarter 20181. * On March 19, 2019, we announced the initiation of a Phase 2 clinical trial evaluating NCX 4251, our novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatment of the eyelid margin for patients with acute exacerbations of blepharitis.  We expect to report top-line results from this Phase 2 trial in the fourth quarter of 2019. * On March 15, 2019, we announced that we had we entered into an exclusive license agreement with Ocumension Therapeutics for the development and commercialization of Nicox’s product ZERVIATE (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis for the Chinese market.  * On January 25, 2019, we announced that we had entered into a bond financing for up to €20 million from Kreos Capital.  The financing is structured as three tranches of which only the first tranche of €8 million has been drawn down.  The exercise of the two other tranches is at Nicox’s sole discretion. * On January 8, 2019 we announced that we had reached the 50% patient enrollment threshold of our multicenter, U.S. Phase 2 clinical trial evaluating our lead product candidate, NCX 470, ahead of schedule.  NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension that has demonstrated 2 to 3 mmHg superior IOP lowering vs. the U.S. market leader LUMIGAN in head-to-head preclinical evaluations.  * Also in January, our global partner, Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies, Inc., received approval in Canada of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%.  VYZULTA is indicated for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. First Quarter 2019 Financial HighlightsAs of March 31, 2019, the Nicox Group had cash and cash equivalents of €23.5 million as compared with €22.0 million at December 30, 2018.  Net revenue2 for the first quarter of 2019 was €0.430 million versus €0.075 million in the first quarter of 2018.    Only the figure related to the cash position of the Nicox Group as of December 31, 2018 is audited; all other figures of this press release are non-audited.  Notes               1. Bloomberg data, comparing the period of the weeks ending 4 January 2019 to 29 March 2019 with the periods of the weeks ending 5 October 2018 to 28 December 2018 and 5 January 2018 to 30 March 2018 2. Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss About NicoxNicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma.  Our portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis.  Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).  In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE™ (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyevance Pharmaceuticals, LLC.  Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverageBryan, Garnier & Co   Hugo Solvet                 Paris, France H.C. Wainwright & Co Yi Chen                        New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Upcoming financial and business conferences May 16    European MidCap Event  Copenhagen, Denmark  June 2-6    BIO 2019    Philadelphia, U.S. June 18-19    European MidCap Event  Paris, France June 19-20    JMP Securities Healthcare Conference    New York, U.S. June 24-25   HealthTech Investor Day  Paris, France ContactsNicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development   T +33 (0)4 97 24 53 00 communications@nicox.com Investors & Media United States & Europe LifeSci Advisors, LLC Hans Herklots T +41 79 598 71 49   hherklots@lifesciadvisors.com Media France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 sophie@lifesciadvisors.comDisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in the 4th chapter of the ‘Document de référence, rapport financier annuel et rapport de gestion 2018’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2019 which are available on Nicox’s website (www.nicox.com).Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99Attachment * EN_2019Q1Results_20190418

  • Désolé, c’est tout ce que nous avons trouvé sur ce sujet.

En utilisant Yahoo vous acceptez les cookies de Yahoo/ses partenaires aux fins de personnalisation et autres usages